The attorneys general of Nebraska, Indiana, and Louisiana filed suit last week to block the Trump administration's order rescheduling medical cannabis from Schedule I to Schedule III under the Controlled Substances Act - a legal challenge that, if successful, would halt one of the most significant shifts in federal drug policy in decades. All three AGs are Republicans, and their core argument is that moving cannabis down the scheduling ladder creates a regulatory runway for eventual adult-use legalization. For licensed cannabis operators, compliance professionals, and the businesses that supply them, the lawsuit introduces new uncertainty around a federal policy shift they had already started factoring into long-term planning.
What the Rescheduling Order Actually Does - and Doesn't Do
It's worth being precise here, because the rescheduling order is narrower than some headlines suggest. The Department of Justice's follow-up order, issued last month after President Trump's December executive order, moved state-regulated medical cannabis products to Schedule III. Adult-use operators remain squarely outside that protection - their products are still federally illegal under Schedule I, meaning operators running adult-use dispensaries are still exposed to federal enforcement risk regardless of how their state licenses are structured.
What Schedule III status does change for medical cannabis is substantial, though. The most financially significant shift: licensed medical cannabis businesses may no longer be subject to IRC Section 280E, the federal tax code provision that bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. For medical dispensaries running tight margins - and most are - the inability to deduct rent, payroll, or cost of goods has functioned as a structural tax penalty for years. Rescheduling, if it holds, could meaningfully change the economics of medical cannabis retail overnight.
The DEA is also planning separate hearings to consider full rescheduling of cannabis out of Schedule I entirely, a process that would apply to all cannabis products, not just medical. That process remains independent of the current DOJ order and would move through a more formal administrative track.
The Political Fault Lines Are More Complicated Than They Look
Nebraska AG Mike Hilgers opposed his own state's medical cannabis legalization ballot initiative in 2024. Roughly 70 percent of Nebraska voters approved it anyway - a margin that makes his decision to redirect taxpayer-funded legal resources toward blocking a federal medical cannabis reform genuinely hard to defend on democratic grounds. His Democratic opponent, former assistant attorney general Jocelyn Brasher, has already called it out directly, arguing that Hilgers is spending public money to challenge a position Nebraska voters made unmistakably clear.
Indiana is a harder case to read. Cannabis remains fully illegal there - no medical program, no adult-use framework. AG Todd Rokita's concern appears to be about what rescheduling signals for the future rather than any immediate disruption to an in-state industry. Louisiana, meanwhile, does operate a state medical cannabis program for patients with specific debilitating conditions, making AG Liz Murrill's position arguably the most internally contradictory of the three - her state has licensed dispensaries dispensing medical cannabis to qualifying patients, yet she's suing to obstruct the federal policy change that would provide those same operators with cleaner tax treatment and reduced federal legal exposure.
What the three share is an ideological concern: that Schedule III status normalizes cannabis federally and greases the slope toward adult-use legalization. That's a policy argument, not a legal one - and courts will have to determine whether it constitutes standing to challenge an executive agency rulemaking.
What Operators and Compliance Teams Should Watch
For licensed cannabis businesses - particularly multi-state operators with medical programs in their portfolio - the lawsuit creates a period of operational ambiguity that compliance teams cannot afford to ignore. Here's the practical tension: the DOJ order is currently in effect. Medical cannabis products in compliant state markets are technically Schedule III as of now. But if a federal court issues an injunction or the lawsuit advances through the courts, that status could be suspended or reversed, potentially mid-year and mid-tax-cycle.
The 280E question is the most pressing operational risk. Businesses that adjust their tax strategy based on Schedule III status - restructuring payroll reporting, deducting previously non-deductible expenses, revising wholesale pricing models - could face significant exposure if the order is blocked retroactively. Accounting and cannabis tax counsel will need to track this case closely. The prudent position, at least until the litigation is resolved, is probably to model both scenarios rather than pivot hard on the assumption that 280E relief is locked in.
Beyond taxes, the lawsuit could affect cannabis banking access and payment infrastructure. Some financial institutions have shown increased willingness to serve medical cannabis operators in anticipation of Schedule III's broader legitimizing effect. A court-ordered pause on the rescheduling order could slow that momentum, keeping medical dispensaries in the restricted-access environment they've worked around for years - relying on cash-heavy operations, limited POS integrations, and workaround payment rails that carry their own compliance burdens.
The rescheduling fight isn't over. It may not be resolved quickly. For operators, the message is straightforward: plan for the upside, but don't operationalize it until the courts weigh in.
